Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: Relevance of the administration sequence

Clinical Cancer Research

Volumn 11, Issue 5, 2005, Pages 1990-1998

  Zupi, Gabriella ^a,b   Scarsella, Marco ^a   Semple, Sean C ^b   Mottolese, Marcella ^a   Natali, Pier G ^a   Leonetti, Carlo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Inex Pharmaceuticals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CISPLATIN; INX 6295; MYC PROTEIN; OBLIMERSEN; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 16344371749     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1284     Document Type: Article

References (26)

1. Biroccio A, Leonetti C, Zupi G. The future of antisense therapy: combination with anticancer treatments. Oncogene 2003;22:6579-88.
2. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-4.
3. Leonetti C, Biroccio A, Candiloro A, et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 1999;5:2588-95.
4. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999;9:51-8.
5. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-42.
6. Grover R, Pacifico MD, Wilson GD, Sanders R. Use of oncogene expression as an independent prognostic marker for primary melanoma. Ann Plast Surg 2003;50:183-7.
7. Grover R, Ross DA, Wilson GD, Sanders R. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma. Br J Plast Surg 1997;50:478-82.
8. Citro G, D'Agnano I, Leonetti C, et al. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998;58:283-9.
9. Grover R, Wilson GD. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur J Surg Oncol 1996;22:347-9.
10. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728-33.
11. Leonetti C, D'Agnano I, Lozupone F, et al. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 1996;88:419-29.
12. D'Alessio S, Margheri F, Pucci M, et al. Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. Int J Cancer 2004;110:125-33.
13. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998;78:1035-42.
14. Wacheck V, Heere-Ress E, Halaschek-Wiener J, et al. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med 2001;79:587-93.
15. Wacheck V, Losert D, Gunsberg P, et al. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 2003;13:393-400.
16. Chi KC, Wallis AE, Lee CH, et al. Effects of Bcl-2 modulation with ODN bcl-2 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat 2000;63:199-212.
17. Miyake H, Hanada N, Nakamura H, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998;16:933-43.
18. Leung S, Miyake H, Zellweger T, Tolcher A, Cleave ME. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001;91:846-50.
19. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995;270:2620-7.
20. Khaled Z, Benimetskaya L, Zeltser R, et al. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1996;24:737-45.
21. Benimetskaya L, Miller P, Benimetsky S, et al. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-α (Isis 3521) and antisense bcl-2 (ODN bcl-2) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol Pharmacol 2001;60:1296-307.
22. Lai JC, Benimetskaya L, Santella RM, Wang Q, Miller PS, Stein CA. ODN bcl-2 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol Cancer Ther 2003;2:1031-43.
23. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-76.
24. Iervolino A, Trisciuoglio D, Ribatti D, et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 2002;16:1453-5.
25. Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 2003;22:8441-7.
26. Elez R, Piiper A, Kronenberger B, et al. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 2003;22:69-80.